Resalis Therapeutics secures €10 million for clinical trials in obesity therapy

Resalis Therapeutics' RES-010: A non-coding RNA-based weight loss program. Sunstone Life Science Ventures participates in Resalis' Series A financing round.

Turin - Resalis Therapeutics announced in a recent press release that it has closed a €10 million Series A financing round. This round was led by Sunstone Life Science Ventures and also includes existing investors such as Claris Ventures and angel investors.

The goal of this financing is to initiate and complete the first Phase 1 clinical trial for its lead program RES-010 in obesity. RES-010 is a non-coding RNA-based compound that aims to provide a transformative therapeutic approach in obesity. This should lead to long-lasting weight loss and prolong the duration of treatment in combination with already approved therapeutics such as GLP-1 receptor agonists.

Clinical phase 1

With the successful completion of the Series A financing round, Resalis plans to advance its therapy, RES-010, into Phase 1 clinical trials and prepare for Phase 2. The funding will also be used to explore the long-lasting effects of RES-010 in combination with existing therapies.

Alessandro Toniolo, CEO of Resalis Therapeutics, emphasized the importance of this milestone and the intention to offer a therapy that specifically reduces fat mass in obesity and has the potential to prolong the efficacy of existing therapies. Claus Andersson, General Partner at Sunstone Life Science Ventures, will also join the Resalis Board of Directors.

Resalis Therapeutics has deep insight into the field of non-coding RNAs (ncRNAs) and RNA-targeted therapeutics in human health and metabolic disorders. Its lead candidate, RES-010, is showing promising results in various preliminary studies in large and small animal models. For more information on Resalis Therapeutics and its developments, the company's website can be visited at www.resalistherapeutics.com.